146 related articles for article (PubMed ID: 28766202)
1. Preoperative Panel Testing for Hereditary Cancer Syndromes Does Not Significantly Impact Time to Surgery for Newly Diagnosed Breast Cancer Patients Compared with BRCA1/2 Testing.
Murphy AE; Hussain L; Ho C; Dunki-Jacobs E; Lee D; Tameron A; Huelsman K; Rice C; Wexelman BA
Ann Surg Oncol; 2017 Oct; 24(10):3055-3059. PubMed ID: 28766202
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
4. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
5. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.
Mislowsky A; Domchek S; Stroede C; Bergey MR; Sonnad SS; Wu L; Tchou J
Ann Surg Oncol; 2011 Mar; 18(3):745-51. PubMed ID: 20972632
[TBL] [Abstract][Full Text] [Related]
7. Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
Gilbert E; Zabor EC; Stempel M; Mangino D; Heerdt A; Pilewskie M
Ann Surg Oncol; 2017 Oct; 24(10):3048-3054. PubMed ID: 28766223
[TBL] [Abstract][Full Text] [Related]
8. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
[TBL] [Abstract][Full Text] [Related]
9. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
10. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
[TBL] [Abstract][Full Text] [Related]
12. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
Woo J; Gwak G; Park I; Bae BN; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Sci Rep; 2021 Jul; 11(1):14747. PubMed ID: 34285295
[TBL] [Abstract][Full Text] [Related]
13. Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer.
Yadav S; Jinna S; Pereira-Rodrigues O; Reeves A; Campian S; Sufka A; Zakalik D
Breast J; 2018 Jul; 24(4):541-548. PubMed ID: 29498445
[TBL] [Abstract][Full Text] [Related]
14. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
Kwong A; Chu AT
Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
16. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
17. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
[TBL] [Abstract][Full Text] [Related]
18. Total skin-sparing mastectomy in BRCA mutation carriers.
Peled AW; Irwin CS; Hwang ES; Ewing CA; Alvarado M; Esserman LJ
Ann Surg Oncol; 2014 Jan; 21(1):37-41. PubMed ID: 23982256
[TBL] [Abstract][Full Text] [Related]
19. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
20. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
